Skip to main content

Table 2 Patient disposition based on cytogenetic risk status

From: Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

  Standard riska High riska,b
Treatment discontinuation, n (%)c D-Vd (n = 137) Vd (n = 136) D-Vd (n = 40) Vd (n = 34)
Patients who discontinued treatment 108 (79) 62 (46) 33 (83) 17 (50)
Reason for discontinuation
 Progressive disease 86 (63) 34 (25) 27 (68) 12 (35)
 Adverse event 11 (8) 15 (11) 5 (13) 3 (9)
 Noncompliance with study drugd 5 (4) 5 (4) 0 1 (3)
 Withdrawal by patient 1 (1) 6 (4) 0 1 (3)
 Death 2 (1) 2 (1) 1 (3) 0
 Physician decision 3 (2) 0 0 0
  1. D-Vd daratumumab/bortezomib/dexamethasone, Vd bortezomib/dexamethasone, FISH fluorescence in situ hybridization
  2. aBased on FISH/karyotyping
  3. bPatients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality
  4. cSafety population
  5. dBased on reason “Patient refused to further study treatment” at “End of treatment”